Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
about
Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.B Cell-Based Treatments in SLE: Past Experience and Current Directions.
P2860
Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@en
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@nl
type
label
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@en
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@nl
prefLabel
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@en
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@nl
P2093
P2860
P1433
P1476
Safety, pharmacokinetics, and ...... a phase 1/2 randomized study.
@en
P2093
Hiroaki Niiro
Junichi Yamamoto
Kazuyoshi Saito
Mitsumasa Kishimoto
Osamu Togo
Rocio Lledo-Garcia
Seiji Yoshizawa
Shinji Morimoto
Shuichiro Tatematsu
P2860
P356
10.3109/14397595.2015.1079292
P50
P577
2015-09-18T00:00:00Z